Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 08-06-2022 | Multiple Myeloma | Review Article

CXCR4-targeted theranostics in oncology

Authors: Andreas K. Buck, Sebastian E. Serfling, Thomas Lindner, Heribert Hänscheid, Andreas Schirbel, Stefanie Hahner, Martin Fassnacht, Hermann Einsele, Rudolf A. Werner

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2022

Abstract

A growing body of literature reports on the upregulation of C-X-C motif chemokine receptor 4 (CXCR4) in a variety of cancer entities, rendering this receptor as suitable target for molecular imaging and endoradiotherapy in a theranostic setting. For instance, the CXCR4-targeting positron emission tomography (PET) agent [⁶⁸ Ga]PentixaFor has been proven useful for a comprehensive assessment of the current status quo of solid tumors, including adrenocortical carcinoma or small-cell lung cancer. In addition, [⁶⁸ Ga]PentixaFor has also provided an excellent readout for hematological malignancies, such as multiple myeloma, marginal zone lymphoma, or mantle cell lymphoma. PET-based quantification of the CXCR4 capacities in vivo allows for selecting candidates that would be suitable for treatment using the theranostic equivalent [¹⁷⁷Lu]/[⁹⁰Y]PentixaTher. This CXCR4-directed theranostic concept has been used as a conditioning regimen prior to hematopoietic stem cell transplantation and to achieve sufficient anti-lymphoma/-tumor activity in particular for malignant tissues that are highly sensitive to radiation, such as the hematological system. Increasing the safety margin, pretherapeutic dosimetry is routinely performed to determine the optimal activity to enhance therapeutic efficacy and to reduce off-target adverse events. The present review will provide an overview of current applications for CXCR4-directed molecular imaging and will introduce the CXCR4-targeted theranostic concept for advanced hematological malignancies.

Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31–82. https://doi.org/10.1016/B978-0-12-411638-2.00002-1.CrossRefPubMedPubMedCentral

Demmer O, Gourni E, Schumacher U, Kessler H, Wester HJ. PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem. 2011;6:1789–91. https://doi.org/10.1002/cmdc.201100320.CrossRefPubMedPubMedCentral

Herrmann K, Lapa C, Wester HJ, Schottelius M, Schiepers C, Eberlein U, et al. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor. J Nucl Med. 2015;56:410–6. https://doi.org/10.2967/jnumed.114.151647.CrossRefPubMed

Hartimath SV, Domanska UM, Walenkamp AM, Rudi AJOD, de Vries EF. [(9)(9)mTc]O(2)-AMD3100 as a SPECT tracer for CXCR4 receptor imaging. Nucl Med Biol. 2013;40:507–17. https://doi.org/10.1016/j.nucmedbio.2013.02.003.CrossRefPubMed

Nimmagadda S, Pullambhatla M, Pomper MG. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. J Nucl Med. 2009;50:1124–30. https://doi.org/10.2967/jnumed.108.061325.CrossRefPubMed

Woodard LE, Nimmagadda S. CXCR4-based imaging agents. J Nucl Med. 2011;52:1665–9. https://doi.org/10.2967/jnumed.111.097733.CrossRefPubMed

Lapa C, Schreder M, Schirbel A, Samnick S, Kortum KM, Herrmann K, et al. [(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma — comparison to [(18)F]FDG and laboratory values. Theranostics. 2017;7:205–12. https://doi.org/10.7150/thno.16576.CrossRefPubMedPubMedCentral

Werner RA, Kircher S, Higuchi T, Kircher M, Schirbel A, Wester HJ, et al. CXCR4-directed imaging in solid tumors. Front Oncol. 2019;9:770. https://doi.org/10.3389/fonc.2019.00770.CrossRefPubMedPubMedCentral

Vag T, Gerngross C, Herhaus P, Eiber M, Philipp-Abbrederis K, Graner FP, et al. First experience with chemokine receptor CXCR4-targeted PET imaging of patients with solid cancers. J Nucl Med. 2016;57:741–6. https://doi.org/10.2967/jnumed.115.161034.CrossRefPubMed

10.

Mayerhoefer ME, Raderer M, Lamm W, Weber M, Kiesewetter B, Rohrbeck J, et al. CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication. Blood. 2022;139:240–4. https://doi.org/10.1182/blood.2021013239.CrossRefPubMedPubMedCentral

11.

Duell J, Krummenast F, Schirbel A, Klassen P, Samnick S, Rauert-Wunderlich H, et al. Improved primary staging of marginal-zone lymphoma by addition of CXCR4-directed PET/CT. J Nucl Med. 2021;62:1415–21. https://doi.org/10.2967/jnumed.120.257279.CrossRefPubMed

12.

Habringer S, Lapa C, Herhaus P, Schottelius M, Istvanffy R, Steiger K, et al. Dual targeting of acute leukemia and supporting niche by CXCR4-directed theranostics. Theranostics. 2018;8:369–83. https://doi.org/10.7150/thno.21397.CrossRefPubMedPubMedCentral

13.

Walenkamp AME, Lapa C, Herrmann K, Wester HJ. CXCR4 ligands: the next big hit? J Nucl Med. 2017;58:77S-82S. https://doi.org/10.2967/jnumed.116.186874.CrossRefPubMed

14.

Buck AK, Stolzenburg A, Hanscheid H, Schirbel A, Luckerath K, Schottelius M, et al. Chemokine receptor — directed imaging and therapy. Methods. 2017;130:63–71. https://doi.org/10.1016/j.ymeth.2017.09.002.CrossRefPubMed

15.

Lapa C, Hanscheid H, Kircher M, Schirbel A, Wunderlich G, Werner RA, et al. Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma. J Nucl Med. 2019;60:60–4. https://doi.org/10.2967/jnumed.118.210997.CrossRefPubMed

16.

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103. https://doi.org/10.1056/NEJMoa2107322.CrossRefPubMedPubMedCentral

17.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427.CrossRefPubMedPubMedCentral

18.

Kaemmerer D, Trager T, Hoffmeister M, Sipos B, Hommann M, Sanger J, et al. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy. Oncotarget. 2015;6:27566–79. https://doi.org/10.18632/oncotarget.4491.CrossRefPubMedPubMedCentral

19.

Werner RA, Weich A, Higuchi T, Schmid JS, Schirbel A, Lassmann M, et al. Imaging of chemokine receptor 4 expression in neuroendocrine tumors — a triple tracer comparative approach. Theranostics. 2017;7:1489–98. https://doi.org/10.7150/thno.18754.CrossRefPubMedPubMedCentral

20.

Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, et al. Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumors. J Nucl Med. 2017;58:91–6. https://doi.org/10.2967/jnumed.116.178095.CrossRefPubMed

21.

Hayes AR, Furtado O’Mahony L, Quigley AM, Gnanasegaran G, Caplin ME, Navalkissoor S, et al. The combined interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in metastatic gastroenteropancreatic neuroendocrine tumors: a classification system with prognostic impact. Clin Nucl Med. 2022;47:26–35. https://doi.org/10.1097/RLU.0000000000003937.CrossRefPubMed

22.

Weich A, Werner RA, Buck AK, Hartrampf PE, Serfling SE, Scheurlen M, et al. CXCR4-directed PET/CT in patients with newly diagnosed neuroendocrine carcinomas. Diagnostics (Basel). 2021;11. https://doi.org/10.3390/diagnostics11040605.

23.

Maurer S, Herhaus P, Lippenmeyer R, Hanscheid H, Kircher M, Schirbel A, et al. Side effects of CXC-chemokine receptor 4-directed endoradiotherapy with pentixather before hematopoietic stem cell transplantation. J Nucl Med. 2019;60:1399–405. https://doi.org/10.2967/jnumed.118.223420.CrossRefPubMedPubMedCentral

24.

Burger M, Glodek A, Hartmann T, Schmitt-Graff A, Silberstein LE, Fujii N, et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene. 2003;22:8093–101. https://doi.org/10.1038/sj.onc.1207097.CrossRefPubMed

25.

Lapa C, Luckerath K, Rudelius M, Schmid JS, Schoene A, Schirbel A, et al. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer—initial experience. Oncotarget. 2016;7:9288–95. https://doi.org/10.18632/oncotarget.7063.CrossRefPubMedPubMedCentral

26.

Chifu I, Heinze B, Fuss CT, Lang K, Kroiss M, Kircher S, et al. Impact of the chemokine receptors CXCR4 and CXCR7 on clinical outcome in adrenocortical carcinoma. Front Endocrinol (Lausanne). 2020;11: 597878. https://doi.org/10.3389/fendo.2020.597878.CrossRef

27.

Altieri B, Ronchi CL, Kroiss M, Fassnacht M. Next-generation therapies for adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2020;34: 101434. https://doi.org/10.1016/j.beem.2020.101434.CrossRefPubMed

28.

Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179:G1–46. https://doi.org/10.1530/EJE-18-0608.CrossRefPubMed

29.

Bluemel C, Hahner S, Heinze B, Fassnacht M, Kroiss M, Bley TA, et al. Investigating the chemokine receptor 4 as potential theranostic target in adrenocortical cancer patients. Clin Nucl Med. 2017;42:e29–34. https://doi.org/10.1097/RLU.0000000000001435.CrossRefPubMed

30.

Li T, Li H, Wang Y, Harvard C, Tan JL, Au A, et al. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma. J Pathol. 2011;223:519–30. https://doi.org/10.1002/path.2829.CrossRefPubMedPubMedCentral

31.

Lapa C, Kircher S, Schirbel A, Rosenwald A, Kropf S, Pelzer T, et al. Targeting CXCR4 with [(68)Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma? Oncotarget. 2017;8:96732–7. https://doi.org/10.18632/oncotarget.18235.CrossRefPubMedPubMedCentral

32.

Lewis R, Habringer S, Kircher M, Hefter M, Peuker CA, Werner R, et al. Investigation of spleen CXCR4 expression by [(68)Ga]Pentixafor PET in a cohort of 145 solid cancer patients. EJNMMI Res. 2021;11:77. https://doi.org/10.1186/s13550-021-00822-6.CrossRefPubMedPubMedCentral

33.

Serfling SE, Lapa C, Dreher N, Hartrampf PE, Rowe SP, Higuchi T, et al. Impact of tumor burden on normal organ distribution in patients imaged with CXCR4-targeted [68Ga]Ga-PentixaFor PET/CT. Mol Imaging Biol. 2022.

34.

Beauregard JM, Hofman MS, Kong G, Hicks RJ. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39:50–6. https://doi.org/10.1007/s00259-011-1937-3.CrossRefPubMed

35.

Sandstrom M, Velikyan I, Garske-Roman U, Sorensen J, Eriksson B, Granberg D, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013;54:1755–9. https://doi.org/10.2967/jnumed.113.120600.CrossRefPubMed

36.

Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Luckerath K, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015;7:477–87. https://doi.org/10.15252/emmm.201404698.CrossRefPubMedPubMedCentral

37.

Pan Q, Cao X, Luo Y, Li J, Feng J, Li F. Chemokine receptor-4 targeted PET/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2020;47:537–46. https://doi.org/10.1007/s00259-019-04605-z.CrossRefPubMed

38.

Herhaus P, Habringer S, Philipp-Abbrederis K, Vag T, Gerngross C, Schottelius M, et al. Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. Haematologica. 2016;101:932–40. https://doi.org/10.3324/haematol.2016.142976.CrossRefPubMedPubMedCentral

39.

Deutsch AJ, Steinbauer E, Hofmann NA, Strunk D, Gerlza T, Beham-Schmid C, et al. Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregulation of CXCR7 is associated with progression to diffuse large B-cell lymphoma. Mod Pathol. 2013;26:182–94. https://doi.org/10.1038/modpathol.2012.134.CrossRefPubMed

40.

Mayerhoefer ME, Raderer M, Lamm W, Pichler V, Pfaff S, Weber M, et al. CXCR4 PET imaging of mantle cell lymphoma using [(68)Ga]Pentixafor: comparison with [(18)F]FDG-PET. Theranostics. 2021;11:567–78. https://doi.org/10.7150/thno.48620.CrossRefPubMedPubMedCentral

41.

Kraus S, Dierks A, Rasche L, Kertels O, Kircher M, Schirbel A, et al. (68)Ga-Pentixafor PET/CT for detection of chemokine receptor CXCR4 expression in myeloproliferative neoplasms. J Nucl Med. 2022;63:96–9. https://doi.org/10.2967/jnumed.121.262206.CrossRefPubMedPubMedCentral

42.

Luo Y, Cao X, Pan Q, Li J, Feng J, Li F. (68)Ga-Pentixafor PET/CT for imaging of chemokine receptor 4 expression in Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma: comparison to (18)F-FDG PET/CT. J Nucl Med. 2019;60:1724–9. https://doi.org/10.2967/jnumed.119.226134.CrossRefPubMedPubMedCentral

43.

Buck AK, Haug A, Dreher N, Lambertini A, Higuchi T, Lapa C, et al. Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using (68)Ga-PentixaFor PET. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.121.263693.CrossRefPubMedPubMedCentral

44.

Keller T, Lopez-Picon FR, Krzyczmonik A, Forsback S, Takkinen JS, Rajander J, et al. Comparison of high and low molar activity TSPO tracer [(18)F]F-DPA in a mouse model of Alzheimer’s disease. J Cereb Blood Flow Metab. 2020;40:1012–20. https://doi.org/10.1177/0271678X19853117.CrossRefPubMed

45.

Schottelius M, Osl T, Poschenrieder A, Hoffmann F, Beykan S, Hanscheid H, et al. [(177)Lu]pentixather: comprehensive preclinical characterization of a first CXCR4-directed endoradiotherapeutic agent. Theranostics. 2017;7:2350–62. https://doi.org/10.7150/thno.19119.CrossRefPubMedPubMedCentral

46.

Hanscheid H, Schirbel A, Hartrampf P, Kraus S, Werner RA, Einsele H, et al. Biokinetics and dosimetry of [(177)Lu]Lu-Pentixather. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.121.262295.CrossRefPubMed

47.

Hanscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with (177)Lu-DOTATATE/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59:75–81. https://doi.org/10.2967/jnumed.117.193706.CrossRefPubMed

48.

Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Hanscheid H, et al. First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease. J Nucl Med. 2016;57:248–51. https://doi.org/10.2967/jnumed.115.167361.CrossRefPubMed

49.

Lapa C, Herrmann K, Schirbel A, Hanscheid H, Luckerath K, Schottelius M, et al. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma. Theranostics. 2017;7:1589–97. https://doi.org/10.7150/thno.19050.CrossRefPubMedPubMedCentral

50.

Sarno J. Prevention and management of tumor lysis syndrome in adults with malignancy. J Adv Pract Oncol. 2013;4:101–6.PubMedPubMedCentral

51.

Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1476–90. https://doi.org/10.1016/j.annonc.2020.08.2099.CrossRefPubMed

52.

Werner RA, Schirbel A, Buck AK, Fassnacht M, Hahner S. Adrenal functional imaging. Presse Med. 2022;51: 104114. https://doi.org/10.1016/j.lpm.2022.104114.CrossRefPubMed

53.

Cancilla D, Rettig MP, DiPersio JF. Targeting CXCR4 in AML and ALL. Front Oncol. 2020;10:1672. https://doi.org/10.3389/fonc.2020.01672.CrossRefPubMedPubMedCentral

54.

Crazzolara R, Kreczy A, Mann G, Heitger A, Eibl G, Fink FM, et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol. 2001;115:545–53. https://doi.org/10.1046/j.1365-2141.2001.03164.x.CrossRefPubMed

55.

Ko SY, Park CJ, Park SH, Cho YU, Jang S, Seo EJ, et al. High CXCR4 and low VLA-4 expression predicts poor survival in adults with acute lymphoblastic leukemia. Leuk Res. 2014;38:65–70. https://doi.org/10.1016/j.leukres.2013.10.016.CrossRefPubMed

56.

Sison EA, McIntyre E, Magoon D, Brown P. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Mol Cancer Res. 2013;11:1004–16. https://doi.org/10.1158/1541-7786.MCR-13-0114.CrossRefPubMedPubMedCentral

57.

Heckmann MB, Reinhardt F, Finke D, Katus HA, Haberkorn U, Leuschner F, et al. Relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease. Circ Cardiovasc Imaging. 2020;13: e010628. https://doi.org/10.1161/CIRCIMAGING.120.010628.CrossRefPubMedPubMedCentral

58.

Werner RA, Koenig T, Diekmann J, Haghikia A, Derlin T, Thackeray JT, et al. CXCR4-targeted imaging of post-infarct myocardial tissue inflammation: prognostic value after reperfused myocardial infarction. JACC Cardiovasc Imaging. 2022;15:372–4. https://doi.org/10.1016/j.jcmg.2021.08.013.CrossRefPubMed

59.

Hess A, Derlin T, Koenig T, Diekmann J, Wittneben A, Wang Y, et al. Molecular imaging-guided repair after acute myocardial infarction by targeting the chemokine receptor CXCR4. Eur Heart J. 2020;41:3564–75. https://doi.org/10.1093/eurheartj/ehaa598.CrossRefPubMed

60.

Reiter T, Kircher M, Schirbel A, Werner RA, Kropf S, Ertl G, et al. Imaging of C-X-C motif chemokine receptor CXCR4 expression after myocardial infarction with [(68)Ga]Pentixafor-PET/CT in correlation with cardiac MRI. JACC Cardiovasc Imaging. 2018;11:1541–3. https://doi.org/10.1016/j.jcmg.2018.01.001.CrossRefPubMed

61.

Werner RA, Thackeray JT, Diekmann J, Weiberg D, Bauersachs J, Bengel FM. The changing face of nuclear cardiology: guiding cardiovascular care toward molecular medicine. J Nucl Med. 2020;61:951–61. https://doi.org/10.2967/jnumed.119.240440.CrossRefPubMedPubMedCentral

62.

Calabretta R, Hoeller C, Pichler V, Mitterhauser M, Karanikas G, Haug A, et al. Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries. Circulation. 2020;142:2396–8. https://doi.org/10.1161/CIRCULATIONAHA.120.048708.CrossRefPubMed

63.

Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136:2085–7. https://doi.org/10.1161/CIRCULATIONAHA.117.030571.CrossRefPubMed

64.

Kircher M, Tran-Gia J, Kemmer L, Zhang X, Schirbel A, Werner RA, et al. Imaging inflammation in atherosclerosis with CXCR4-directed (68)Ga-Pentixafor PET/CT: correlation with (18)F-FDG PET/CT. J Nucl Med. 2020;61:751–6. https://doi.org/10.2967/jnumed.119.234484.CrossRefPubMed

65.

Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong C, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013;19:357–66. https://doi.org/10.1158/1078-0432.CCR-12-2333.CrossRefPubMed

Title: CXCR4-targeted theranostics in oncology
Authors: Andreas K. Buck
Sebastian E. Serfling
Thomas Lindner
Heribert Hänscheid
Andreas Schirbel
Stefanie Hahner
Martin Fassnacht
Hermann Einsele
Rudolf A. Werner
Publication date: 08-06-2022
Publisher: Springer Berlin Heidelberg
Keywords: Multiple Myeloma
Adrenocortical Carcinoma
Molecular Imaging
Mantle Cell Lymphoma
Positron Emission Tomography
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2022
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05849-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

CXCR4-targeted theranostics in oncology

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2022

Predicting response of micrometastases with MIRDcell V3: proof of principle with 225Ac-DOTA encapsulating liposomes that produce different activity distributions in tumor spheroids

Repair of α-particle-induced DNA damage in peripheral blood mononuclear cells after internal ex vivo irradiation with 223Ra

PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617

A prospective head-to-head comparison of 68 Ga-NOTA-3P-TATE-RGD and 68 Ga-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours

Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up